ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1119

Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice
Abstract Number: 1120

Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients
Abstract Number: 1121

Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Abstract Number: 1122

The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy
Abstract Number: 1123

Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016
Abstract Number: 1124

A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China
Abstract Number: 1125

A Rheumatologic Clinical Profile of the VEXAS Syndrome: Results from a Survey Conducted Among Rheumatologic Units of 126 Hospitals Across Spain
Abstract Number: 1126

Identification of Clinical Phenotypes in Behçet’s Disease Using a Cluster Analysis
Abstract Number: 1127

Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis
Abstract Number: 1128

Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review
Abstract Number: 1129

Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study
Abstract Number: 1130

Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI
Abstract Number: 1131

Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort
Abstract Number: 1132

Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases
Abstract Number: 1133

Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].